Reports Q4 revenue $128.615M, consensus $127.02M. Joe Todisco, CorMedix (CRMD) Chairman and CEO, commented, “I am proud of the Company’s progress over the past year as we have accelerated the expansion of patient access for DefenCath, completed our acquisition and integration of Melinta, and saw progress in our two ongoing Phase 3 clinical programs for Rezzayo prophylaxis and DefenCath in TPN. With the announcement of our share repurchase program and multiple near-term milestones on the horizon, most notably the Rezzayo ReSPECT phase III data, CorMedix is focused on driving business growth and shareholder value over the year ahead.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CRMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Low P/E Alert! These 3 Undervalued Stocks Are Poised to Surge Over 90%
- Cormedix: Rezzayo and DefenCath Prophylaxis Upside Underscores Buy Rating and $13 DCF-Based Target
- Cormedix: Steady Near-Term Base with High-Impact Label Expansion Catalysts Justifying a Buy Rating
- CorMedix board authorizes share repurchase program of up to $75M